The Color of Stem Cells
By Josef Tayag,
The Greenlining Institute
| 09. 09. 2005
Why the benefits of stem cell research might not be for people like me.
After losing half of one of my lungs to tuberculosis while
volunteering in the Andes last year, I assumed that life would
just never be the same again. By this I meant that the flight
of stairs to my apartment would always seem twice as long and
that I would have to give up things I enjoyed like taking long
runs on Sunday mornings.
However, the promise of therapeutic treatments derived from
stem cell research gives individuals like me a hope for normalcy.
Yet, as an immigrant from a low-income family, I can’t
stop from cringing at the thought that the low-income and marginalized
communities of the state still have no explicit guarantee of
access to the promised 'cures' of Prop. 71—much less to
adequate health care in general.
Last Friday, the Independent Citizen’s Oversight Committee
(ICOC) allocated a little over $39 million to prestigious research
institutions like UCLA, UC Berkeley, Stanford, USC, and Cal
Tech among others. Yet, it’s unclear from perusing through
many of their grant proposals just how much focus these research
institutions will give to communities...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...